(NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, will present new data at the American Association of Cancer ...
SAN DIEGO--(BUSINESS WIRE)--Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today ...
SAN DIEGO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor ...
SAN DIEGO, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company pioneering the development of ...
CLD-101, a neural stem cell-based oncolytic virotherapy, shows safety and feasibility in a phase 1 trial for recurrent high-grade glioma. The trial involves up to four weekly intracerebral doses, with ...
Calidi Biotherapeutics Inc. has announced that Northwestern University/Northwestern Memorial Hospital is starting recruitment for its CLD-101 clinical trial, which evaluates a new immunotherapy ...
Sartorius announces the launch of the CellCelector CLD, an automated imaging and cell isolation platform designed to simplify ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results